Real-world clinical outcome and safety of adjuvant human Interferon-alpha1b in resected stage IIIB or IIIC melanoma: results of a retrospective study

Meiyan Gao,Yuehua Li,Wenjing Tang,Yu Liu,Weinan Guo,Tao Zhao,Jianhong Zhao,Jin’e Zhang,Guannan Zhu,Chunying Li,Tianwen Gao,Qiong Shi
DOI: https://doi.org/10.1007/s44178-024-00087-8
2024-01-01
Holistic Integrative Oncology
Abstract:Human interferon-α1b (hIFN-α1b) is the first genetically engineered drug approved by the National Medical Product Administration for cancer therapy in China. hIFN-α1b is a relatively safe therapy and can improve survival in advanced melanoma and its long-term efficacy against resection of stage III melanoma is unknown. The objective of this study is to assess the safety and efficacy of hIFN-α1b in patients with resected stage III melanoma. The clinical data were collected from patients who underwent resection of stage IIIB or IIIC melanoma and received subcutaneous injection of hIFN-α1b every other day. The efficacy of hIFN-α1b was determined by rate of recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS). Safety data were acquired by review of adverse events at follow-ups. The study included a total of 61 patients. The median follow-up duration was 45 months. The RFS at 12, 24, and 36 months were observed to be 75.4
What problem does this paper attempt to address?